OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor
出版年份 2020 全文链接
标题
OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor
作者
关键词
-
出版物
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 64, Issue 6, Pages -
出版商
American Society for Microbiology
发表日期
2020-03-26
DOI
10.1128/aac.02020-19
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Management of drug-resistant tuberculosis
- (2019) Christoph Lange et al. LANCET
- Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis
- (2018) Mamoru Fujiwara et al. TUBERCULOSIS
- Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles
- (2018) Lu Xiong et al. RSC Advances
- Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious DiseasesIn VivoPharmacology Workshop for TB Drug Development
- (2016) Eric Nuermberger et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Delamanid in the treatment of multidrug-resistant tuberculosis
- (2016) R. Gupta et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Unexpected high prevalence of resistance-associatedRv0678variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
- (2016) Cristina Villellas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tuberculosis
- (2016) Keertan Dheda et al. LANCET
- Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice
- (2016) Scott M. Irwin et al. ACS Infectious Diseases
- The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis
- (2015) Vadim Makarov et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis
- (2015) Rokeya Tasneen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The structural use of carbostyril in physiologically active substances
- (2015) Toshihiko Tashima BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis
- (2015) S. M. Irwin et al. Disease Models & Mechanisms
- Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis
- (2015) Tawanda Gumbo et al. JOURNAL OF INFECTIOUS DISEASES
- Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
- (2015) Stephen K. Field Therapeutic Advances in Chronic Disease
- Moxifloxacin Retains Antimycobacterial Activity in the Presence of gyrA Mutations
- (2014) M. McGrath et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis
- (2014) Monalisa Chatterji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Towards a new combination therapy for tuberculosis with next generation benzothiazinones
- (2014) V. Makarov et al. EMBO Molecular Medicine
- Discovery of Pyrazolopyridones as a Novel Class of Noncovalent DprE1 Inhibitor with Potent Anti-Mycobacterial Activity
- (2014) Manoranjan Panda et al. JOURNAL OF MEDICINAL CHEMISTRY
- New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
- (2014) Eric Leibert et al. Therapeutics and Clinical Risk Management
- Bactericidal Activity and Mechanism of Action of AZD5847, a Novel Oxazolidinone for Treatment of Tuberculosis
- (2013) V. Balasubramanian et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
- (2013) Giovanna Riccardi et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Identification of a small molecule with activity against drug-resistant and persistent tuberculosis
- (2013) F. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosis
- (2012) Emily R. Driver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors
- (2012) S. M. Batt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis
- (2012) J. Neres et al. Science Translational Medicine
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis
- (2011) Rokeya Tasneen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Decaprenylphosphoryl-β-D-Ribose 2-Epimerase from Mycobacterium tuberculosis is a Magic Drug Target
- (2010) G. Manina et al. CURRENT MEDICINAL CHEMISTRY
- Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis
- (2009) Kathy N. Williams et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
- (2009) V. Makarov et al. SCIENCE
- Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy
- (2008) Beata A. Wolucka FEBS Journal
- Preclinical testing of new drugs for tuberculosis: current challenges
- (2008) Anne J. Lenaerts et al. TRENDS IN MICROBIOLOGY
- Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5–MmpL5 efflux system
- (2008) Anna Milano et al. TUBERCULOSIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started